A synchronized plunge in traditional safe havens and digital assets has erased over $10 trillion in value, signaling a broad market reassessment of Federal Reserve policy and global liquidity conditions.
A Utah couple with a $180,000 income sought advice on using a $7,300 bonus. Dave Ramsey's firm counsel: shore up emergency savings, attack their HELOC debt, and postpone both a long-awaited honeymoon and speculative IPO investing until their financial foundation is secure.
A new report from crypto market maker Wintermute Ventures forecasts a seismic shift, arguing that blockchain-based prediction markets will begin displacing traditional insurance by making hyper-specific risks tradable. The firm outlines a future where decentralized infrastructure becomes the new clearing layer for a programmable global economy.
While Colgate-Palmolive's stock has trailed the S&P 500 over the past year, Wall Street analysts see a resilient business model and strong international presence supporting long-term growth, maintaining a 'Moderate Buy' consensus.
As Kevin Warsh emerges as a frontrunner for Federal Reserve Chair, former colleagues paint a picture of a consensus-seeking listener. But with the Fed facing internal divisions and external pressure, questions remain: Is his collaborative style the steady hand needed, or a potential liability in times of crisis?
Alibaba Group is making a massive, multi-billion yuan bet to integrate its Qwen AI assistant across its ecosystem and develop its own AI chips, signaling a strategic pivot to reduce foreign dependency and deepen user engagement amid intense competition.
Shoppers are bracing for another wave of price increases as new import taxes take effect, targeting a range of everyday items from spirits to seafood. Experts warn the hikes will squeeze household budgets and force tough choices at the supermarket.
As economic pressures mount, flexible remote work opportunities are evolving. We examine four proven side gigs that experts project can still generate significant weekly earnings from home in the coming years.
Analyst firm Benchmark increased its price target for specialty food distributor The Chefs' Warehouse (CHEF) to $84, maintaining a Buy rating. The move follows strong operational performance, including domestic acquisitions and double-digit international growth in the Middle East.
IDEXX Laboratories reports robust fourth-quarter and full-year 2025 results, with double-digit revenue growth fueled by record instrument placements and strategic innovations like InVue DX and CancerDx. The company provides a confident outlook for 2026, targeting continued organic growth despite sector headwinds.
For retirees seeking to increase their monthly income, re-entering the workforce may offer a path to higher Social Security payments—with important considerations.
H.C. Wainwright maintains a Buy rating on Lexeo Therapeutics but slashes its price target, citing persistent market doubts over the company's PKP2 cardiomyopathy program despite encouraging early clinical results.
Aptiv PLC sees mixed but upwardly revised price targets from major analysts, with Piper Sandler upgrading the auto tech supplier to Overweight and naming it a top pick for 2026, citing its pragmatic strategy and attractive valuation.
Despite recent guidance revisions, Mobileye Global retains strong buy ratings from analysts who see significant upside potential, as the company positions 2026 for a strategic transition in the autonomous driving sector.
H.C. Wainwright and Chardan Capital upgrade Korro Bio (KRRO) to Buy, citing the independent potential of its RNA-editing asset KRRO-121 and strong preclinical data as key catalysts.
Disney CEO Bob Iger confirmed that AI-generated videos from OpenAI's Sora will begin appearing on Disney+ within months, framing the move as an additive feature for short-form content while downplaying any ripple effects on the company's traditional film and TV pipeline.
Wall Street's top analysts made waves Monday with revised ratings on key stocks, highlighting a growing divergence in tech and retail outlooks as earnings season approaches.
While Apis Capital's flagship fund posted stellar 2025 returns, its latest investor letter spotlights the ongoing divergence of opinion on AI pure-plays like C3.ai, where heavy investment needs clash with market expectations for profitability.
The Apis Flagship Fund reported robust quarterly and annual gains for 2025, significantly beating global benchmarks. While highlighting its performance drivers, the fund's investor letter also discussed its position on gene therapy firm uniQure (QURE).
Apis Capital's flagship fund, which surged 55% in 2025, spotlights clinical-stage biotech Celcuity in its latest investor letter, citing the company's novel platform for matching cancer patients with targeted therapies.
